AVS
Mark Toland is the CEO of AVS. Before joining AVS, Mark served as the President and CEO of Corindus where he transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. The Siemens Healthineers acquisition of Corindus for $1.1 billion was the fifth largest medical technology acquisition of 2019.
This person is not in any offices
AVS
AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. They are redefining interventional therapy for severely calcified lesions with their Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device.